

# Todd E Defor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415555/publications.pdf>

Version: 2024-02-01

40  
papers

5,014  
citations

623188

14  
h-index

433756

31  
g-index

40  
all docs

40  
docs citations

40  
times ranked

5517  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors and outcomes of flares in chronic graft-versus-host disease. Bone Marrow Transplantation, 2022, , .	1.3	3
2	High cutaneous amphiregulin expression predicts fatal acute <sc>graftâ€versusâ€host</sc> disease. Journal of Cutaneous Pathology, 2022, , .	0.7	2
3	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Advances, 2022, , .	2.5	1
4	Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , .	1.3	0
5	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. Blood Advances, 2021, 5, 1352-1359.	2.5	14
6	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Advances, 2021, 5, 1425-1436.	2.5	39
7	Infusion reactions in natural killer cell immunotherapy: a retrospective review. Cytotherapy, 2021, 23, 627-634.	0.3	7
8	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. Transplantation and Cellular Therapy, 2021, 27, 667.e1-667.e5.	0.6	6
9	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Advances, 2020, 4, 2317-2324.	2.5	1
10	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biology of Blood and Marrow Transplantation, 2019, 25, 56-62.	2.0	9
11	Hematopoietic Cell Transplantâ€Related Toxicities and Mortality in Frail Recipients. Biology of Blood and Marrow Transplantation, 2019, 25, 2454-2460.	2.0	27
12	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances, 2019, 3, 1970-1980.	2.5	164
13	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. Modern Pathology, 2019, 32, 560-567.	2.9	10
14	Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. JCI Insight, 2019, 4, .	2.3	18
15	SEMI-PARAMETRIC REGRESSION MODEL FOR RECURRENT BACTERIAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. Statistica Sinica, 2019, 29, 1489-1509.	0.2	1
16	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood, 2018, 131, 2515-2527.	0.6	307
17	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunology, Immunotherapy, 2018, 67, 483-494.	2.0	74
18	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Advances, 2018, 2, 1882-1888.	2.5	27

#	ARTICLE	IF	CITATIONS
19	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	0.6	333
20	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 866-872.	2.0	19
21	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
22	An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 81-88.	2.0	9
23	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863.	0.6	357
24	Intermittent Zoledronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2012, 120, 1965-1965.	0.6	0
25	Association of Iron Overload with Survival and Complications in Allogeneic Hematopoietic Cell Transplant Recipients: Prospective Cohort Study Using R2-MRI Measured Liver Iron Content. <i>Blood</i> , 2012, 120, 1961-1961.	0.6	8
26	Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System. <i>Blood</i> , 2012, 120, 2011-2011.	0.6	14
27	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. <i>Blood</i> , 2011, 117, 1061-1070.	0.6	926
28	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010, 116, 225-225.	0.6	6
29	Impact of Graft Source on Immune Recovery: Comparisons Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. <i>Blood</i> , 2010, 116, 3731-3731.	0.6	0
30	Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Cerebral Variant Adrenoleukodystrophy: A Modern, Single-Institution Experience. <i>Blood</i> , 2010, 116, 3543-3543.	0.6	1
31	Reduced Intensity Versus Myeloablative Conditioning in Adults with Acute Myeloid Leukemia Transplanted with Umbilical Cord Blood. <i>Blood</i> , 2010, 116, 3531-3531.	0.6	0
32	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. <i>Blood</i> , 2007, 110, 3064-3070.	0.6	489
33	New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses.. <i>Blood</i> , 2007, 110, 41-41.	0.6	3
34	Incidence and Outcomes of Immune Thrombocytopenia (ITP) Following Hematopoietic Stem Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 1316-1316.	0.6	0
35	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. <i>Blood</i> , 2005, 105, 3051-3057.	0.6	1,574
36	Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.. <i>Blood</i> , 2005, 106, 842-842.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Pulmonary Risk Factors in Allogeneic Transplantation for Hurler Syndrome.. Blood, 2004, 104, 2154-2154.	0.6	3
38	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. Blood, 2004, 104, 1817-1817.	0.6	0
39	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. Blood, 2004, 104, 2148-2148.	0.6	0
40	Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biology of Blood and Marrow Transplantation, 2002, 8, 387-394.	2.0	367